Suggested remit: To appraise the clinical and cost effectiveness of durvalumab with tremelimumab within its marketing authorisation for untreated non-small-cell lung cancer with no epidermal growth factor receptor - or anaplastic-lymphoma-kinase -positive mutations.
Status In progress
Process STA 2018
ID number 1143

Provisional Schedule

Expected publication 08 January 2020

Project Team

Project lead Emily Richards

Email enquiries


Key events during the development of the guidance:

Date Update
24 January 2018 - 21 February 2018 Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators
26 June 2017 In progress, Topic referred
21 April 2017 Referral

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance